10 studies on Ghrh receptor mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**Peptide secretagogues do not merely turn up GH output — they fundamentally reshape the kinetics of each burst**, a finding with direct implications for dosing strategy. Clinicians and researchers using combined **GH…
**Clinicians and biohackers using sermorelin or GHRP-2** should recognize that abdominal fat is the dominant suppressor of combined secretagogue synergy — not simply age or low testosterone. **Reducing AVF before or a…
**Clinicians and researchers testing GH-axis function must control for age, estrogen status, and visceral fat simultaneously** — failing to account for any single factor can produce spurious group differences in secre…
**Clinicians and peptide users designing GH-stimulation protocols in women must account for menopausal status and concurrent estrogen exposure, not just dosing of the secretagogue itself.** The finding that GHRP-2 out…
**GHRH antagonists such as MZ-5-156 may have therapeutic utility not only as antiproliferatives but as suppressors of iNOS-driven nitrosative and oxidative stress in lung cancer**, a dual mechanism that broadens their…
This research suggests that GHRH agonists like sermorelin and its more potent analogs could be a powerful therapeutic tool for improving recovery after a heart attack. For biohackers or clinicians exploring regenerati…
**Clinicians managing thalassemia-related growth failure** should note that standard stimulation testing may miss subnormal ultradian GH secretion, meaning affected patients could benefit from secretagogue-based proto…
**Stacking GHRH with a GHS like MK-677 may not linearly amplify hypothalamic activation** — endogenous GH released by either agent appears to dampen arcuate responsiveness through a shared feedback ceiling, explaining…
**The existence of a deeply conserved GHS-R strongly supports the eventual identification of an endogenous ghrelin-axis ligand**, providing a rational pharmacological target for reversing age-related GH decline. For c…
**Chronic ipamorelin pretreatment uniquely sensitises the pituitary somatotroph population** to respond to subsequent GHS or GHRH stimulation — a 'priming' phenomenon that does not occur after equivalent chronic GHRH …